Go Back


  • Serving its partners and customers in over 100 countries
  • Employs over 7,600 qualified personnel
  • Introduced CANMAb™ - Trastuzumab for Treating Breast Cancer in India
  • As of March 2015, total assets stood at Rs 2,651 crore (US$ 431.05 million)

Biocon, India's largest biotech company is focused on delivering affordable innovation. The company is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.

Biocon's key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.

Biocon’s aspiration to become a US$ 1 billion company by FY18 is fuelled by five powerful growth accelerators, small molecules, biosimilars, branded formulations, novel molecules, and research services with a focus on emerging markets.

Dr Kiran Mazumdar Shaw, Chairman & MD, Biocon (India) was awarded the 2015 AIB Fellows Executive of the Year Award by Carlson School of Management at the University of Minnesota at the 56th Annual AIB Conference.

Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 100 countries.


Biocon: Fully integrated biopharmaceutical company

2015 Syngene International Limited, the research arm of Biocon, lists on the BSE and NSE
2014 Syngene, a subsidiary of Biocon Group, in collaboration with Baxter sets up a dedicated Research and Development Center at Biocon Park
2013 Biocon Unveils Biocon Academy - A center of excellence for advanced learning in applied biosciences
2008 Biocon becomes the 7th largest biotech employer in the world (Med Ad News)
2000 Biocon establishes Clinigene, India's first clinical research organisation (CRO) to pursue clinical R&D
1989 Biocon is the first Indian biotech company to receive US funding for proprietary technologies
1979 Biocon is the first Indian company to manufacture and export enzymes to USA and Europe


Updated: September, 2015

India's pharmaceutical sector will touch US$ 45 billion by 2020.
x IBEF : India Brand Equity Foundation